Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.




  • Lung Cancer — Management of HER2-mutated Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancers (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. Human epidermal growth factor 2 (HER2) is a critical ... more >>
  • Lung Cancer — Integration of Antibody-Drug Conjugates into Current Management of NSCLC – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. HER2 is a critical player in the EGFR/ErbB2 signaling ... more >>
  • Lung Cancer — Overview of HER2 in Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. Human epidermal growth factor 2 (HER2) is a critical player ... more >>
  • Cancer Care Considerations — IASLC: Emerging SCLC Therapies Target B7-H3 – BreakingMED
  • Although notoriously difficult to treat, the cell surface landscape of small cell lung cancer (SCLC) offers promising targets that are ripe for the development of antibody-drug conjugates (ADCs), researchers suggested during a special symposium presented at the International Association for the study of Lung ... more >>
    V. Abramson, MD
  • Lung Cancer — Management of HER2-Overexpressing Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. HER2 is a critical player in the EGFR/ErbB2 signaling ... more >>
  • Lung Cancer — IASLC: ADC Pipeline Gains Velocity in NSCLC – BreakingMED
  • Three antibody-drug conjugates—trastuzumab deruxtecan (T-DXd), patritumab deruxtecan, and datopotamab deruxtecan (Dato-DXd)—are gaining attention as a potential additional line of therapy for patients with advanced non-small cell lung cancer (NSCLC), per a presentation that was part of a special symposium at ... more >>
    V. Abramson, MD
  • Lung Cancer — Management of a Patient With KRAS-Mutant Metastatic NSCLC – @Point of Care Chapter
  • This case illustrates the real-life clinical scenario of a former smoker who is diagnosed with non-small cell lung cancer adenocarcinoma with a KRAS G12C mutation. This case demonstrates the palliative effect the newly approved agent sotorasib can have in patients with KRAS G12C mutations, but also highlights ... more >>
  • Lung Cancer — IASLC: Real-World Use of Amivantamab Mirrors Clinical Trial Results – BreakingMED
  • New data presented at IASLC’s World Conference on Lung Cancer suggest that, among patients with NSCLC with EGFR exon 20 insertions, amivantamab performs as well in the real-world setting as it did in previous clinical trials that led to drug’s approval.
    V. Abramson, MD
  • Lung Cancer — IASLC: QoL Benefit Seen for NSCLC Treated with Cemiplimab – BreakingMED
  • Patients who had non-small cell lung cancer (NSCLC) with high levels of PD-L1 expression achieved measurable improvements in quality of life when treated with the monoclonal antibody cemiplimab versus platinum-doublet chemotherapy, according to a post-hoc analysis of data from the EMPOWER-Lung 1 clinical ... more >>
    V. Abramson, MD
  • Lung Cancer — IASLC: Amivantamab Plus Lazertinib Demonstrates Efficacy in Advanced EGFR-Mutant NSCLC – BreakingMED
  • Combination treatment with a combination of amivantamab plus lazertinib achieved a durable response among treatment-naive patients with EGFR-mutant non-small cell lung cancer (NSCLC), according to a small substudy of the CHRYSALIS trial presented at IASLC’s World Conference on Lung Cancer.
    V. Abramson, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Lung Cancer — Management of HER2-mutated Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancers (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. Human epidermal growth factor 2 (HER2) is a critical ... more >>
  • Lung Cancer — Integration of Antibody-Drug Conjugates into Current Management of NSCLC – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. HER2 is a critical player in the EGFR/ErbB2 signaling ... more >>
  • Lung Cancer — Management of HER2-Overexpressing Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. HER2 is a critical player in the EGFR/ErbB2 signaling ... more >>
  • Lung Cancer — Overview of HER2 in Lung Cancer – Webcast
  • Development of treatments that specifically target driver mutations has led to a new era in the treatment of non-small cell lung cancer (NSCLC), allowing for more patients who had previously had poor prognosis to improve outcomes and quality of life. Human epidermal growth factor 2 (HER2) is a critical player ... more >>
  • Prostate Cancer — AE Management for Combination PARPi and AR-Targeted Therapies and Considerations for Managing mCRPC in the African-American Community – Webcast
  • Treatment of patients is an art as well as a science. Part of the art is knowing how to discuss treatment options with patients, which includes discussing potential adverse events associated with each treatment option. Another part is making sure to tailor treatment to the individual patient—but not ... more >>
  • Prostate Cancer — Biomarkers of PARPi Sensitivity and Examining the Data on Combination PARPi and AR-Targeted Therapies in mCRPC – Webcast
  • Although targeting the androgen pathway has been a mainstay of prostate cancer treatment for some time, greater understanding of prostate tumor development and progression has led to use of agents targeting other important molecular pathways in this disease. One such pathway involves repair of DNA damage, ... more >>
  • Prostate Cancer — Understanding the Mechanism of Action for PARP Inhibitors and Androgen Receptor-Targeted Therapies in mCRPC – Webcast
  • Although targeting the androgen pathway has been a mainstay of prostate cancer treatment for some time, greater understanding of prostate tumor development and progression has led to use of agents targeting other important molecular pathways in this disease. One such pathway involves repair of DNA damage, ... more >>
  • Multiple Sclerosis — Neurology Morning Commute: Getting UP to Speed on Multiple Sclerosis Management – Podcast
  • With the many treatments now available for the treatment of multiple sclerosis (MS), our faculty reviews this impressive therapeutic landscape and discusses how to choose the best ones for the individual MS patient.
  • Multiple Sclerosis — Neurology Morning Commute: Multiple Sclerosis and the S1P Receptor Upgrade – Podcast
  • In this episode, our faculty looks at the latest treatments for multiple sclerosis—the newest sphingosine-1-phosphate receptor modulators. What is their mechanism of action? Which patients would benefit from them, and how are side effects and toxicities managed with these latest treatment options?
  • Multiple Sclerosis — Neurology Morning Commute: Covid-19 Vaccines and Disease-Modifying Treatments for MS – Podcast
  • Are there issues with getting the Covid-19 vaccine and boosters for patients with MS who are on disease-modifying therapies? In this podcast our faculty discuss the safety and efficacy of the vaccines, timing with disease-modifying therapies, and monoclonal antibodies for prevention and treatment.
  • ALS — Case Study: Management of a Patient Newly Diagnosed With Amyotrophic Lateral Sclerosis – Case Study
  • Treatment options for amyotrophic lateral sclerosis (ALS) have expanded in recent years with the availability of disease-modifying and symptomatic therapies that can be offered to individuals living with ALS and have the potential to improve the quality and the length of their lives. In addition, ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • Diabetes — Utilization of SGLT-2 Inhibitor Therapy for the Primary Prevention of Cardiovascular Events in a Patient With T2DM – Case Study
  • The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a class of agents that lower glucose but have also recently been shown to have effects on reducing cardiovascular and renal morbidities. This case illustrates the clinical scenario of a patient with type 2 diabetes mellitus (T2DM) who was initiated on ... more >>
  • Cardiology Care Considerations — Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic – Case Study
  • The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... more >>
    P. Dorian, MD
  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • Heart Failure — Patient With Worsening HFrEF and Prediabetes – Case Study
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... more >>
    J. Butler, MD, MPH, MBA
  • Heart Failure — Patient With Worsening HFrEF and Multiple Hospitalizations – Case Study
  • Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... more >>
    J. Udelson, MD
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information